Related by context. All words. (Click for frequent words.) 73 statistically significant differences 72 reach statistical significance 72 nonsignificant 68 statistically significant reduction 68 statistical significance 67 clinically meaningful 65 statistically significant improvement 65 statistically significant p 64 statistically significant p = 64 P = .# 62 achieved statistical significance 61 statistically significant correlation 61 placebo 61 statistically insignificant 60 p = 60 statistically nonsignificant 59 univariate analysis 59 tertile 59 attain statistical significance 59 p = #.# [002] 59 lumbar spine BMD 58 multivariate adjustment 58 demonstrated statistically significant 58 achieve statistical significance 58 multivariate analysis 58 nonfatal MI 58 definite stent thrombosis 58 Subgroup analyzes 58 multivariable analysis 57 endometrial thickness 57 primary endpoint 57 LVEF 57 clinically meaningful differences 57 QTcF 57 Kaplan Meier analysis 57 CVD mortality 57 univariate 56 statistically significant correlations 56 posttreatment 56 MMSE score 56 p = .# [002] 56 hippocampal volume 56 secondary endpoints 56 oxycodone CR 56 secondary endpoint 56 placebo p 56 NIHSS score 56 primary efficacy endpoint 56 NIHSS 56 HbA1C levels 56 nondiabetic patients 55 fasting insulin 55 tertiles 55 intima media thickness 55 % CI #.#-#.# [002] 55 Secondary endpoints included 55 cardiovascular mortality 55 noninferiority 55 #mg/day [001] 55 MADRS score 55 adenoma recurrence 55 HbA 1c 55 HOMA IR 55 multivariate Cox 55 placebo p = 55 p = #.# [004] 55 postintervention 55 clinically relevant 55 prespecified 55 serum concentrations 55 NIH CPSI 55 nonrandomized 55 BMI z 55 prospective cohort 55 ticagrelor 55 plasma leptin 55 Univariate analysis 54 prospectively defined 54 tiotropium 54 locoregional recurrence 54 biochemical recurrence 54 HbA1c levels 54 binary restenosis 54 Multivariate analyzes 54 subgroup analyzes 54 highest tertile 54 pCR 54 6MWD 54 non inferiority 54 thromboembolic events 54 systolic BP 54 carotid IMT 54 serum estradiol 54 virologic response 54 randomized 54 NNRTI resistance 54 TEAEs 54 ADAS cog 54 #.#/#.# mmHg [001] 54 symptomatic VTE 54 nonsignificant difference 54 multivariable adjustment 54 Baseline characteristics 54 morphometric vertebral fractures 54 highest quintile 54 covariate 54 serum parathyroid hormone 53 colorectal adenomas 53 advanced adenomas 53 primary endpoints 53 CHD mortality 53 HBeAg negative patients 53 clinically meaningful improvement 53 serum BDNF 53 PASI scores 53 colorectal adenoma 53 tapentadol ER 53 Crohn Disease Activity 53 albumin excretion rate 53 inverse association 53 n = 53 achieved ACR# 53 composite endpoint 53 Secondary endpoints 53 demonstrated clinically meaningful 53 femoral neck BMD 53 serum vitamin D 53 serum uric acid 53 virologic failure 53 reinfarction 53 creatinine ratio 53 statistically significant predictor 53 SGRQ 53 unfractionated heparin 53 HbA 1c levels 53 Subgroup analysis 53 elevated ALT 53 mg kg dose 53 carotid plaque 53 eplerenone 53 myocardial infarctions 53 intima media thickness IMT 53 confidence interval CI 53 serum urate 53 ABC/3TC 53 ± SD 53 serum triglycerides 53 systolic blood pressure 53 placebo fluoxetine 53 doxorubicin docetaxel 53 PSADT 53 median PFS 53 inflammatory biomarkers 53 ipsilateral stroke 53 CI -#.# 53 nmol L 53 hip BMD 53 p = .# [001] 53 serum calcium 53 logistic regression model 53 YMRS 53 tipranavir r 53 methotrexate monotherapy 53 primary efficacy endpoints 53 HBeAg seroconversion 53 ≥ 53 % CI #.#-#.# [007] 53 ANOVA 53 Kaplan Meier survival 53 CLA supplementation 53 virologic 53 coronary calcification 53 hydroxyvitamin D levels 53 dose Iluvien 53 stent binary restenosis 53 depressive symptoms 53 nonsignificant trend 53 hsCRP levels 52 lowest tertile 52 multivariate analyzes 52 depressive symptom 52 tirofiban 52 desvenlafaxine succinate 52 discontinuations due 52 platelet reactivity 52 extrapyramidal symptoms 52 NYHA functional class 52 inflammatory lesions 52 serum creatinine levels 52 ADAS Cog 52 montelukast 52 baseline HbA1c 52 LV dysfunction 52 timepoint 52 PSA nadir 52 sd = 52 mg dose 52 Hb A1C 52 atheroma volume 52 liver transaminases 52 progression TTP 52 fosamprenavir 52 plasma cortisol 52 insulin glargine 52 CCyR 52 ziprasidone 52 undetectable HBV DNA 52 surrogate endpoint 52 symptom exacerbation 52 interobserver reliability 52 TDF FTC 52 DAS# [002] 52 logistic regression analyzes 52 ACUITY trial 52 clinically meaningful improvements 52 dietary calcium intake 52 univariate analyzes 52 LEXIVA r 52 logistic regression analysis 52 timepoints 52 recurrent venous thromboembolism 52 XIENCE V demonstrated 52 Secondary endpoints include 52 symptom severity 52 HER2 expression 52 plasma concentrations 52 airway responsiveness 52 carotid intima media 52 clinically insignificant 52 hemoglobin A1c HbA1c 52 CC genotype 52 secondary efficacy endpoints 52 peginterferon alfa 2b 52 tumor histology 52 evaluable 52 neutrophil counts 52 mg ustekinumab 52 beta carotene supplementation 52 intraobserver 52 % Confidence Interval 52 % CI #.#-#.# [006] 52 genotypic resistance 52 histologic 52 WOMAC scores 52 QTc 52 Hazard Ratio HR 52 telmisartan 52 substudy 52 MADRS 52 transaminase elevations 52 Cmax 52 UPDRS scores 52 fructosamine 52 advanced adenoma 52 IPSS 52 WOMAC pain 52 nonresponders 51 ADCS ADL 51 FEV1 51 serum IGF 51 interquartile range 51 CIMZIA TM certolizumab pegol 51 creatinine levels 51 mL/min/#.# m 2 51 sirolimus eluting stent 51 vicriviroc 51 quartiles 51 abacavir lamivudine 51 normotensive 51 urinary calcium 51 CR nPR 51 #mg BID [001] 51 mammographic density 51 Rating Scale MADRS 51 certolizumab 51 spine BMD 51 g dL 51 MMSE scores 51 visceral adiposity 51 Index CDAI 51 Primary endpoints 51 neurologic progression 51 NEVO ™ 51 infarct size 51 VT VF 51 sustained virologic response 51 diastolic blood pressure 51 logistic regression models 51 Brief Psychiatric 51 preoperative PSA 51 ramipril 51 tumor progression TTP 51 cortical thickness 51 postoperative mortality 51 PSA kinetics 51 multivariable adjusted 51 glycated hemoglobin HbA1c 51 serum retinol 51 mg QD 51 thiazide diuretics 51 Kaplan Meier curves 51 confidence interval #.#-#.# 51 endotoxin exposure 51 selenium supplementation 51 insulin detemir 51 Montgomery Åsberg Depression 51 conjugated equine estrogen 51 Observational studies 51 β blockers 51 observational studies 51 nadroparin 51 pioglitazone 51 liver histology 51 nonvertebral fractures 51 NYHA class 51 ATACAND 51 etanercept 51 μmol L 51 lipid lowering medications 51 periprocedural 51 SNP rs# [002] 51 lipid lowering drugs 51 LPV r 51 fasting glucose levels 51 AUC0 51 plasma folate 51 ZOMIG Nasal Spray 51 systolic 51 bivariate 51 arterial thromboembolic events 51 DHA supplementation 51 serum ALT 51 severe exacerbations 51 laboratory abnormalities 51 annualized relapse 51 subanalysis 51 abdominal circumference 51 elevated bilirubin 51 randomized controlled 51 triglyceride concentrations 51 symptomatic intracerebral hemorrhage 51 sUA 51 elevated troponin 51 correlational 51 surrogate markers 51 serum cotinine 51 viral kinetic 51 antibody titer 51 asthma exacerbations 51 ibandronate 51 peak VO2 51 recurrent ischemia 51 Montgomery Asberg Depression 51 DAS# remission 51 PANSS scores 51 flow mediated dilation 51 Bonferroni correction 51 subgroup 51 covariates 51 seroprotection 51 placebo controlled trials 51 tHcy 51 lowest quintile 51 serum PSA 51 lispro 50 estimated GFR 50 neurodevelopmental impairment 50 exhaled nitric oxide 50 elevated LDH 50 biochemical relapse 50 complete cytogenetic response 50 colorectal cancer incidence 50 EDSS score 50 HAQ DI 50 NHANES III 50 nonobese 50 sirolimus eluting stents 50 CLBP 50 vertebral fracture 50 Y BOCS 50 stent thromboses 50 p = #.# [003] 50 HBeAg 50 posttransplant 50 confidence intervals CIs 50 apnea hypopnea index 50 QTc intervals 50 noninferior 50 solifenacin 50 adalimumab 50 hormone receptor negative 50 nondiabetics 50 rs# [004] 50 octreotide LAR 50 plus methotrexate 50 interobserver 50 noncancer 50 subscale scores 50 APTIVUS r 50 MACCE 50 noncarriers 50 periprocedural MI 50 squamous histology 50 DAS# CRP 50 alteplase 50 FDA defined valvulopathy 50 Multivariate analysis 50 lipid profiles 50 plasma lipid 50 thromboembolic 50 HIV RNA 50 UACR 50 methacholine challenge 50 sirolimus stent 50 FOLFOX4 50 serum homocysteine 50 randomized clinical 50 radiographic progression 50 cotinine levels 50 baseline CD4 50 CD4 + cell 50 experienced virologic failure 50 dose proportionality 50 meta analytic 50 paricalcitol 50 pregabalin 50 DLQI 50 CI #.#-#.# [002] 50 statistical significance p 50 atazanavir ritonavir 50 chlorthalidone 50 CFQ R 50 post hoc 50 nmol L. 50 valsartan 50 nonfatal stroke 50 retinal thickness 50 endoscopic remission 50 log# 50 HAM D 50 ropivacaine 50 creatinine clearance 50 subclinical cardiovascular disease 50 Kaplan Meier curve 50 A1c levels 50 IV bisphosphonates 50 adverse perinatal 50 SSRI citalopram 50 Secondary efficacy endpoints 50 MetS 50 interobserver agreement 50 5-FU/LV 50 adiponectin concentrations 50 ezetimibe simvastatin 50 RNFL thickness 50 endobronchial dysplasia 50 #mg BID [003] 50 HDRS 50 Apgar scores 50 troponin T 50 hypoglycemic events 50 #OHD levels 50 alanine aminotransferase 50 urodynamic parameters 50 noncardiac 50 hemoglobin A1c levels 50 mRS 50 polyp recurrence 50 virologic responses 50 oral prednisolone 50 nmol liter 50 TT genotype 50 GIK infusion 50 hydroxyvitamin D concentrations 50 dietary folate 50 oxcarbazepine 50 teriflunomide 50 SVR# 50 pharmacokinetic interaction 50 % CI #.#-#.# [008] 50 borderline statistical significance 50 mg doses 50 pharmacokinetics PK 50 postoperative complications 50 KIF6 carriers 50 LDL particle 50 achieving PASI 50 postoperative complication 50 Doxil ® 50 virological response 50 serum cholesterol 50 abciximab 50 log# copies mL 50 CsA 50 epidemiologic studies 50 linaclotide treated 50 gout flare 50 residual confounding 50 p = NS 49 Psoriasis Area 49 plasma glucose 49 % CI #.#-#.# [003] 49 viral load 49 hypertensives 49 tumor shrinkage 49 coronary artery calcification 49 candesartan 49 creatine kinase 49 bezafibrate 49 perioperative complications 49 seroconversion 49 ADCS CGIC 49 severe hypoglycemia 49 HbA1C 49 incontinence episodes 49 dapagliflozin plus 49 paclitaxel eluting stents 49 NPH insulin 49 macrovascular 49 salivary cortisol 49 ejection fractions 49 myocardial infarctions MIs 49 mg BID 49 serum phosphate 49 d dimer 49 colorectal neoplasia 49 dalteparin 49 eptifibatide 49 serum triglyceride 49 androgen suppression 49 lipid lowering therapy 49 mucosal healing 49 HbA1c 49 AST ALT 49 Alzheimer Disease Assessment 49 avosentan 49 linear regression analyzes 49 vaginal progesterone gel 49 left ventricular systolic 49 df = 49 SCr 49 multivariable Cox 49 zoledronic acid 49 lignan intake 49 MDRD 49 CI = 49 lamotrigine 49 sustained virological response 49 multivariate logistic regression 49 multiple logistic regression 49 serum urate levels 49 ketorolac 49 retrospective cohort 49 fondaparinux 49 DES implantation 49 estimated glomerular filtration 49 correlated inversely 49 VcMP 49 protein excretion 49 HbA 1C 49 cerebrovascular events 49 intact parathyroid hormone 49 T2 lesions 49 IFN alfa 49 familial clustering 49 lanthanum carbonate 49 myocardial infarction MI 49 GERD symptom 49 DLTs 49 osteopenic 49 serum phosphorus 49 median CD4 49 placebo controlled studies 49 hemoglobin concentration 49 P ≤ 49 systolic blood pressures 49 postprocedure 49 ventricular tachyarrhythmia 49 eGFR 49 serum testosterone 49 EDSS scores 49 Scale cognitive subscale 49 aminotransferase levels 49 FOLPI 49 Fasting plasma glucose 49 microbleeds 49 MMSE 49 tenofovir DF 49 HRQoL 49 thyrotropin levels 49 apolipoprotein B 49 urinary albumin 49 diastolic BP 49 postop 49 free survival PFS 49 thrombolytic therapy 49 PASI score 49 biologically plausible 49 valacyclovir 49 recurrent ischemic 49 SUVmax 49 URTI 49 correlation 49 Univariate 49 active comparator 49 beta blocker therapy 49 XIENCE V PROMUS Stent 49 PANSS total 49 mmHg diastolic 49 SerDes transceivers 49 recurrent VTE 49 ARB telmisartan 49 NSTEMI 49 -#.# log# copies mL 49 clodronate 49 placebo controlled 49 baseline FEV 49 risedronate 49 Kaplan Meier estimates 49 serum aminotransferase levels 49 subclinical hyperthyroidism 49 Insulin sensitivity 49 serum albumin 49 Breslow thickness 49 elevated liver enzymes 49 Pharmacokinetic 49 regression coefficient 49 ADHD RS 49 specific antigen PSA 49 nondepressed 49 caspofungin 49 viral kinetics 49 SHBG levels 49 mineral density 49 aminotransferase ALT 49 hemoglobin concentrations 49 HIV HCV coinfected 49 undetectable viral load 49 β = 49 strongest predictor 49 diuretic chlorthalidone 49 arterial thickening 49 BPH Symptom Score 49 HORIZONS AMI trial 49 leukocyte count 49 serum CRP 49 macrovascular disease 49 Torsades de Pointes 49 severe hypoglycemic 49 conditional logistic regression 49 cilostazol 49 LEXIVA 49 endometrial hyperplasia 49 serum selenium 49 placebo dexamethasone 49 sociodemographic factors 48 mcg albinterferon alfa 2b 48 neurocognitive function 48 subthreshold depression 48 corrected QT interval 48 clinico pathological 48 UPDRS 48 glycated hemoglobin levels 48 DAS# scores 48 posttest 48 nonfatal myocardial infarction 48 everolimus eluting stents 48 perioperative mortality 48 lactate dehydrogenase 48 T2 lesion volume 48 pamidronate 48 neostigmine 48 fluoxetine 48 secondary efficacy endpoint 48 rimonabant #mg 48 imatinib therapy 48 irbesartan 48 ± SEM 48 μg kg 48 LV ejection fraction 48 prespecified secondary 48 #mg dose [003] 48 median survivals 48 thrombotic events 48 observational study 48 pharmacodynamic PD 48 EDSS 48 antibody titers 48 iniparib 48 echocardiographic 48 creatine supplementation 48 Stent thrombosis 48 nonusers 48 PaO 2 48 dose dependently 48 RBP4 levels 48 aminotransferases 48 mcg BID 48 Epidemiological studies 48 gross hematuria 48 mg d 48 HBeAg positive patients 48 pharmacodynamic 48 dobutamine 48 #μg [002] 48 intracerebral hemorrhage 48 oral diclofenac 48 VADT 48 alanine aminotransferase ALT 48 TRITON TIMI 48 leucopenia 48 Ki# 48 mg RDEA# 48 aPTT 48 dexmedetomidine 48 bivariate analysis 48 rCBF 48 FOSRENOL ® 48 racemic albuterol 48 multivariable logistic regression 48 lopinavir r 48 #mm Hg 48 antioxidant supplementation 48 rosuvastatin #mg 48 eszopiclone 48 clinicopathological 48 psychosocial variables 48 preintervention 48 PSQI 48 intravaginal ejaculatory latency 48 copies mL 48 HIV seroconversion 48 treat NNT 48 postoperatively 48 proportional hazards 48 interquartile range IQR 48 NATRECOR ® 48 seropositivity 48 angiotensin converting enzyme inhibitors 48 nephrotoxicity 48 correlation coefficients 48 plus MTX 48 Mania Rating Scale 48 glycosylated hemoglobin 48 abacavir 48 viremia 48 limiting generalizability 48 lung function 48 bivariate analyzes 48 clinically meaningful reductions 48 dose statin therapy 48 intussusception 48 extracapsular extension 48 β blocker 48 leukopenia 48 serum lipid 48 nonexposed 48 SLNB 48 pulmonary exacerbations 48 tic severity 48 Negative Syndrome 48 distant metastases 48 darunavir 48 discontinuations 48 IELT 48 Kaplan Meier method 48 IOP lowering 48 bone mineral 48 flavonoid intake 48 darunavir ritonavir 48 parkinsonian symptoms 48 regression analysis 48 ULORIC 48 mcg kg 48 pramipexole 48 heavily pretreated 48 bosentan 48 BMI waist circumference 48 inversely associated 48 CNS LS 48 umol L 48 diameter stenosis 48 plasma pharmacokinetics 48 strontium ranelate 48 Ishak fibrosis score 48 scintigraphic 48 nicardipine 48 serum sodium levels 48 clinically meaningful efficacy 48 pentoxifylline 48 eosinophil count 48 serum lipid levels 48 axial length 48 Unified Parkinson Disease 48 serum markers 48 triglyceride concentration 48 parous women 48 systolic dysfunction 48 COMT genotype 48 rs# [003] 48 mcg dose 48 tapentadol IR 48 randomized controlled trials 48 strongest predictors 48 baseline PASI 48 = #.#-#.# 48 comorbidity 48 inert placebo 48 angiographic outcomes 48 HRQOL 48 CANCIDAS 48 neurodevelopmental outcome 48 olmesartan 48 HDL cholesterol triglycerides 48 coinfected patients 48 NAbs 48 TNF blocker therapy 48 PANSS 48 serum sodium 48 splenectomized patients 48 r = 48 liver transplant recipients 48 ELBW infants 48 ALSFRS R 48 dacarbazine chemotherapy 48 locoregional 48 serum leptin 48 nonfasting triglycerides 48 confounders 48 pretest probability 48 cTnT levels 48 euthyroid 48 ertapenem 48 recurrent glioblastoma multiforme 48 equol producers 48 atorvastatin #mg 48 micafungin 48 bivalirudin 48 lopinavir r arm 48 nodal metastases 48 RRMS patients 48 -#.# mg dL [001] 48 intravenous bisphosphonates 48 LDB CPR 48 hsCRP 48 renal toxicity 48 iodixanol 48 IM progesterone 48 comorbidities 48 PRADAXA #mg 48 correlated 48 haemorrhagic stroke 48 tolvaptan 48 hematologic toxicity 48 B vitamin supplementation 48 efficacy endpoint 48 serum cotinine levels 48 EQ 5D 48 spontaneous preterm delivery 48 dyspnea 48 chlorambucil 48 virologic suppression 48 Pain Intensity 48 preterm deliveries 48 IL#B 48 simvastatin ezetimibe 48 left ventricular dysfunction 48 Carotid Revascularization Endarterectomy vs. 48 oral ibandronate 48 ventricular enlargement 48 lipid parameters 48 CR CRu 48 meta regression 48 lymphopenia 48 QTc interval 48 glycoprotein IIb IIIa inhibitors 48 ACR# response 48 paliperidone ER 47 serum phosphate levels 47 cardioprotective effects 47 Fonarow 47 mg BID dose 47 causal relationship 47 coronary stenosis 47 regression analyzes 47 mg/m2 dose 47 serum lipids 47 -#.# mm Hg 47 bolus dose 47 serum GGT 47 ± 47 S/GSK# 47 rotigotine 47 salmeterol fluticasone propionate 47 poorer prognosis 47 ACR# responses 47 tegaserod 47 Plasma concentrations 47 upper gastrointestinal bleeding 47 REYATAZ r arm 47 HAM D# 47 cognitive function 47 #ng/ml 47 #.#ng/ml 47 somatic symptom 47 mild renal impairment 47 severe periodontitis 47 dose clopidogrel 47 left ventricular ejection 47 Xalatan R 47 systolic diastolic 47 cardiovascular morbidity 47 UPDRS motor 47 fasting serum 47 colesevelam HCl 47 prolonged QT interval 47 fasting triglyceride levels 47 subclinical hypothyroidism 47 somatostatin analog 47 QTc prolongation 47 urate levels 47 SORT OUT III 47 habitual snoring 47 ventricular mass 47 macroalbuminuria 47 ximelagatran 47 CK # plasma 47 advanced neoplasia 47 serum cortisol 47 glycosylated hemoglobin HbA1c 47 pravastatin 47 rt PA 47 confounder 47 baseline FEV1 47 neoadjuvant chemotherapy 47 PSA velocity 47 AUA Symptom Score 47 Adverse events 47 quetiapine 47 #mg QD [001] 47 sweat chloride 47 inhaled budesonide 47 concomitant antibiotics 47 circulating IGF 47 rs# [002] 47 mIU L 47 infliximab 47 socioeconomic deprivation 47 fasting plasma 47 adjuvant radiotherapy 47 serum magnesium 47 arterial occlusion 47 liver metastasis 47 acute bronchospasm 47 acute coronary 47 darbepoetin alpha 47 cabazitaxel 47 odds ratios ORs 47 Score DAS# 47 Pred Forte 47 metformin monotherapy 47 cystatin C 47 histopathological 47 KRAS status 47 receiving APTIVUS r 47 carotid atherosclerosis 47 fluorouracil 47 thromboembolism 47 EpCAM expression 47 serum glucose 47 meta analysis 47 thyroglobulin 47 alanine transaminase 47 randomized clinical trials 47 nmol l 47 birthweight 47 subclinical atherosclerosis 47 neuropathological 47 inhibin B 47 tibolone 47 adiponectin levels 47 #.#mg/dL 47 CrCl 47 mg kg 47 serum HBV DNA 47 nocturnal hypoglycaemia 47 serum potassium 47 estramustine 47 TOP2A 47 concomitant medications 47 exhaled NO 47 mcg QD 47 divalproex 47 allele frequencies 47 lumbar spine bone 47 ug dose 47 microemboli 47 headache nasopharyngitis 47 pretreatment baseline